Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.
Califf
R M
RM
Department of Medicine, Duke University Medical Center, Durham, N.C., USA.
Mark
D B
DB
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy*
D005343:Fibrinolytic Agents